Legis Daily

PFAS Accountability Act of 2021

USA117th CongressHR-2751| House 
| Updated: 10/19/2021
Madeleine Dean

Madeleine Dean

Democratic Representative

Pennsylvania

Cosponsors (9)
Mondaire Jones (Democratic)Debbie Dingell (Democratic)Daniel T. Kildee (Democratic)Sean Patrick Maloney (Democratic)Brendan F. Boyle (Democratic)Marilyn Strickland (Democratic)Jerrold Nadler (Democratic)Marie Newman (Democratic)Rashida Tlaib (Democratic)

Environment Subcommittee, Judiciary Committee, Constitution and Limited Government Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
PFAS Accountability Act of 2021 This bill provides a cause of action under the Toxic Substances Control Act for individuals or classes of individuals who were significantly exposed to perfluoroalkyl or polyfluoroalkyl substances, commonly referred to as PFAS. These substances are man-made and may have adverse human health effects. A variety of products contain the compounds, such as nonstick cookware or weatherproof clothing. Specifically, the bill provides a cause of action those who were significantly exposed to PFAS (or have reasonable grounds to believe they were exposed) against persons who engaged in any portion of a manufacturing process that created the PFAS and foresaw (or reasonably should have foreseen) the creation or use of PFAS would result in human exposure. The bill authorizes a court to award medical monitoring to claimants if (1) they have been significantly exposed to PFAS, (2) they have an increased risk of developing a disease associated with such exposure, (3) the increased risk provides a reasonable basis to conclude that periodic diagnostic medical examinations is necessary, and (4) the medical examinations are effective in detecting a disease associated with PFAS exposure. The bill establishes a presumption of significant exposure to PFAS if the claimant (1) provides medical results proving the presence of PFAS in the body, or (2) demonstrates the defendant's manufacturing process created the PFAS to which the claimant was exposed and the PFAS were released into one or more areas where the claimant would have been exposed for at least one year.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-2626
PFAS Accountability Act of 2019
Apr 22, 2021

Latest Companion Bill Action

S 117-1334
Introduced in Senate
Apr 22, 2021
Introduced in House
Apr 22, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 23, 2021
Referred to the Subcommittee on Environment and Climate Change.
Oct 19, 2021
Referred to the Subcommittee on the Constitution, Civil Rights, and Civil Liberties.
  • Bill from Previous Congress

    HR 116-2626
    PFAS Accountability Act of 2019


  • April 22, 2021

    Latest Companion Bill Action

    S 117-1334
    Introduced in Senate


  • April 22, 2021
    Introduced in House


  • April 22, 2021
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • April 23, 2021
    Referred to the Subcommittee on Environment and Climate Change.


  • October 19, 2021
    Referred to the Subcommittee on the Constitution, Civil Rights, and Civil Liberties.

Environmental Protection

Related Bills

  • S 117-1334: PFAS Accountability Act of 2021
Blood and blood diseasesCivil actions and liabilityEnvironmental assessment, monitoring, researchEnvironmental healthFederal district courtsHazardous wastes and toxic substancesHealth care costs and insuranceHealth care coverage and accessHealth promotion and preventive careManufacturingMedical researchMedical tests and diagnostic methodsPollution liability

PFAS Accountability Act of 2021

USA117th CongressHR-2751| House 
| Updated: 10/19/2021
PFAS Accountability Act of 2021 This bill provides a cause of action under the Toxic Substances Control Act for individuals or classes of individuals who were significantly exposed to perfluoroalkyl or polyfluoroalkyl substances, commonly referred to as PFAS. These substances are man-made and may have adverse human health effects. A variety of products contain the compounds, such as nonstick cookware or weatherproof clothing. Specifically, the bill provides a cause of action those who were significantly exposed to PFAS (or have reasonable grounds to believe they were exposed) against persons who engaged in any portion of a manufacturing process that created the PFAS and foresaw (or reasonably should have foreseen) the creation or use of PFAS would result in human exposure. The bill authorizes a court to award medical monitoring to claimants if (1) they have been significantly exposed to PFAS, (2) they have an increased risk of developing a disease associated with such exposure, (3) the increased risk provides a reasonable basis to conclude that periodic diagnostic medical examinations is necessary, and (4) the medical examinations are effective in detecting a disease associated with PFAS exposure. The bill establishes a presumption of significant exposure to PFAS if the claimant (1) provides medical results proving the presence of PFAS in the body, or (2) demonstrates the defendant's manufacturing process created the PFAS to which the claimant was exposed and the PFAS were released into one or more areas where the claimant would have been exposed for at least one year.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

HR 116-2626
PFAS Accountability Act of 2019
Apr 22, 2021

Latest Companion Bill Action

S 117-1334
Introduced in Senate
Apr 22, 2021
Introduced in House
Apr 22, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 23, 2021
Referred to the Subcommittee on Environment and Climate Change.
Oct 19, 2021
Referred to the Subcommittee on the Constitution, Civil Rights, and Civil Liberties.
  • Bill from Previous Congress

    HR 116-2626
    PFAS Accountability Act of 2019


  • April 22, 2021

    Latest Companion Bill Action

    S 117-1334
    Introduced in Senate


  • April 22, 2021
    Introduced in House


  • April 22, 2021
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • April 23, 2021
    Referred to the Subcommittee on Environment and Climate Change.


  • October 19, 2021
    Referred to the Subcommittee on the Constitution, Civil Rights, and Civil Liberties.
Madeleine Dean

Madeleine Dean

Democratic Representative

Pennsylvania

Cosponsors (9)
Mondaire Jones (Democratic)Debbie Dingell (Democratic)Daniel T. Kildee (Democratic)Sean Patrick Maloney (Democratic)Brendan F. Boyle (Democratic)Marilyn Strickland (Democratic)Jerrold Nadler (Democratic)Marie Newman (Democratic)Rashida Tlaib (Democratic)

Environment Subcommittee, Judiciary Committee, Constitution and Limited Government Subcommittee, Energy and Commerce Committee

Environmental Protection

Related Bills

  • S 117-1334: PFAS Accountability Act of 2021
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Blood and blood diseasesCivil actions and liabilityEnvironmental assessment, monitoring, researchEnvironmental healthFederal district courtsHazardous wastes and toxic substancesHealth care costs and insuranceHealth care coverage and accessHealth promotion and preventive careManufacturingMedical researchMedical tests and diagnostic methodsPollution liability